SpaceX’s Healthcare Plays
In this week’s edition of InnovationRx, we look at SpaceX’s hopes for healthcare, the AI drug discovery startup…
Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results
NDA submitted for neladalkib in TKI pre-treated advanced ALK-positive NSCLC NDA for zidesamtinib in TKI pre-treated advanced ROS1-positive…
A Closer Look at Valuation as New ALK Inhibitor Data Presentation Approaches
Nuvalent (NUVL) has scheduled a webcast to present pivotal data from its Phase 1/2 ALKOVE-1 study. The presentation…
Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer
Encore pivotal efficacy and safety data from the ARROS-1 trial also to be presented during poster session CAMBRIDGE,…
Nuvalent to Participate in the UBS 2025 Virtual Oncology Day
CAMBRIDGE, Mass., Sept. 24, 2025 /PRNewswire/ — Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies…